Targeting metastasis-initiating cells through the fatty acid receptor CD36

Area of Science:

• Oncology
• Cancer Biology
• Metabolism

Background:

• The identity of cells initiating metastasis, a key challenge in cancer therapy, remains largely unknown.
• Understanding these cells is crucial for developing effective antimetastatic treatments.

Purpose of the Study:

• To identify and characterize the specific cell population responsible for initiating metastasis in human oral carcinomas.
• To investigate the role of lipid metabolism and the CD36 receptor in metastasis initiation and progression.

Main Methods:

• Characterization of CD44bright cells in human oral carcinomas.
• Assessment of metastatic potential following palmitic acid or high-fat diet administration.
• Inhibition of metastasis using CD36-neutralizing antibodies in orthotopic mouse models.
• Clinical correlation analysis of CD36+ metastasis-initiating cells with patient prognosis.

Main Results:

• A subpopulation of CD44bright cells was identified as metastasis-initiating cells (MICs), characterized by high CD36 expression and lipid metabolism genes.
• Dietary lipids, specifically palmitic acid, enhanced the metastatic potential of CD36+ MICs in a CD36-dependent manner.
• CD36 blockade with neutralizing antibodies significantly inhibited metastasis in preclinical cancer models with no observed side effects.
• Clinical data showed a correlation between CD36+ MICs and poor prognosis across various carcinoma types.

Conclusions:

• Metastasis-initiating cells critically depend on dietary lipids for their pro-metastatic functions.
• Targeting CD36 represents a promising therapeutic strategy to inhibit cancer metastasis across multiple carcinoma types.
• Blocking CD36 offers a potential side-effect-free approach to combat cancer spread.